WO2003062469A3 - Gene matn3 or matrilin-3 linked to osteoarthritis treatment - Google Patents

Gene matn3 or matrilin-3 linked to osteoarthritis treatment Download PDF

Info

Publication number
WO2003062469A3
WO2003062469A3 PCT/IB2003/000342 IB0300342W WO03062469A3 WO 2003062469 A3 WO2003062469 A3 WO 2003062469A3 IB 0300342 W IB0300342 W IB 0300342W WO 03062469 A3 WO03062469 A3 WO 03062469A3
Authority
WO
WIPO (PCT)
Prior art keywords
matn3
gene
matrilin
linked
osteoarthritis treatment
Prior art date
Application number
PCT/IB2003/000342
Other languages
French (fr)
Other versions
WO2003062469A2 (en
Inventor
Stefan Einar Stefansson
Original Assignee
Decode Genetics Ehf
Stefan Einar Stefansson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics Ehf, Stefan Einar Stefansson filed Critical Decode Genetics Ehf
Priority to AU2003201737A priority Critical patent/AU2003201737A1/en
Publication of WO2003062469A2 publication Critical patent/WO2003062469A2/en
Publication of WO2003062469A3 publication Critical patent/WO2003062469A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag

Abstract

A role of the muman MATN3 gene in osteoarthritis is disclosed. Methods for diagnosis, prediction of clinical course and treatment for osteoarthritis using polymorphisms in the MATN3 gene are also disclosed.
PCT/IB2003/000342 2002-01-25 2003-01-23 Gene matn3 or matrilin-3 linked to osteoarthritis treatment WO2003062469A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003201737A AU2003201737A1 (en) 2002-01-25 2003-01-23 Gene matn3 or matrilin-3 linked to osteoarthritis treatment

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US45370502P 2002-01-25 2002-01-25
US5731202A 2002-01-25 2002-01-25
US60/453,705 2002-01-25
US43153802P 2002-12-05 2002-12-05
US60/431,538 2002-12-05

Publications (2)

Publication Number Publication Date
WO2003062469A2 WO2003062469A2 (en) 2003-07-31
WO2003062469A3 true WO2003062469A3 (en) 2004-06-10

Family

ID=32397832

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/000342 WO2003062469A2 (en) 2002-01-25 2003-01-23 Gene matn3 or matrilin-3 linked to osteoarthritis treatment

Country Status (1)

Country Link
WO (1) WO2003062469A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0408685D0 (en) * 2004-04-19 2004-05-19 Guys & St Thomas Hospital Trus Diagnostic method
GB0408684D0 (en) * 2004-04-19 2004-05-19 Guy S And St Thomas Hospital N Diagnostic method
EP2285399A2 (en) * 2008-05-22 2011-02-23 Schering Corporation Egf-a domain-mediated modulation of pcsk9 for treating lipid disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073479A1 (en) * 1999-05-28 2000-12-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073479A1 (en) * 1999-05-28 2000-12-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BELLUOCCIO D ET AL: "Characterization of human matrilin-3 (MATN3).", GENOMICS. UNITED STATES 1 NOV 1998, vol. 53, no. 3, 1 November 1998 (1998-11-01), pages 391 - 394, XP002243331, ISSN: 0888-7543 *
BELLUOCCIO D ET AL: "Matrilin-3 from chicken cartilage.", FEBS LETTERS. NETHERLANDS 29 SEP 1997, vol. 415, no. 2, 29 September 1997 (1997-09-29), pages 212 - 216, XP002243332, ISSN: 0014-5793 *
BRIGGS MICHAEL D ET AL: "Pseudoachondroplasia and multiple epiphyseal dysplasia: mutation review, molecular interactions, and genotype to phenotype correlations.", HUMAN MUTATION. UNITED STATES MAY 2002, vol. 19, no. 5, May 2002 (2002-05-01), pages 465 - 478, XP002243335, ISSN: 1098-1004 *
CHAPMAN K L ET AL: "Mutations in the region encoding the von Willebrand factor A domain of matrilin-3 are associated with multiple epiphyseal dysplasia.", NATURE GENETICS. UNITED STATES AUG 2001, vol. 28, no. 4, August 2001 (2001-08-01), pages 393 - 396, XP002243334, ISSN: 1061-4036 *
STEFÁNSSON STEFÁN EINAR ET AL: "Genomewide scan for hand osteoarthritis: a novel mutation in matrilin-3.", AMERICAN JOURNAL OF HUMAN GENETICS. UNITED STATES JUN 2003, vol. 72, no. 6, June 2003 (2003-06-01), pages 1448 - 1459, XP002243329, ISSN: 0002-9297 *
UNGER S ET AL: "Pseudoachondroplasia and multiple epiphyseal dysplasia: New etiologic developments.", AMERICAN JOURNAL OF MEDICAL GENETICS. UNITED STATES 2001 WINTER, vol. 106, no. 4, January 2001 (2001-01-01), pages 244 - 250, XP002243336, ISSN: 0148-7299 *
WAGENER R ET AL: "Primary structure of matrilin-3, a new member of a family of extracellular matrix proteins related to cartilage matrix protein (matrilin-1) and von Willebrand factor.", FEBS LETTERS. NETHERLANDS 11 AUG 1997, vol. 413, no. 1, 11 August 1997 (1997-08-11), pages 129 - 134, XP002243333, ISSN: 0014-5793 *
WAGENER R ET AL: "Structure and mapping of the mouse matrilin-3 gene (Matn3), a member of a gene family containing a U12-type AT-AC intron.", MAMMALIAN GENOME: OFFICIAL JOURNAL OF THE INTERNATIONAL MAMMALIAN GENOME SOCIETY. UNITED STATES FEB 2000, vol. 11, no. 2, February 2000 (2000-02-01), pages 85 - 90, XP002243330, ISSN: 0938-8990 *

Also Published As

Publication number Publication date
WO2003062469A2 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
WO2004028341A3 (en) Susceptibility gene for human stroke; methods of treatment
WO2002074992A3 (en) Phosphodiesterase 4d genes related to human stroke
EP1539930A4 (en) Multi-step method for the differentiation of insulin positive, glucose
AU2003286567A1 (en) Methods for the treatment of skin disorders
SG116501A1 (en) Composition for heart disease, method to prepare same and uses thereof.
HK1157215A1 (en) Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme n--4-
AU2003280298A1 (en) Methods for the biological treatment of gas
WO2004055162A3 (en) Modulation of endothelial lipase expression
AU2002309750A1 (en) Screening, diagnostic and therapeutic methods relating to riz
WO2002022871A3 (en) Polymorphic bone morphogenetic protein 2
AU2003291536A1 (en) Method for the diagnosis and treatment of vascular disease
WO2004009024A3 (en) Modulation of protein kinase c-iota expression
WO2004081229A3 (en) Use of bv8 and/or eg-vegf to promote hematopoiesis
WO2004048522A3 (en) Modulation of huntingtin interacting protein 2 expression
WO2004043394A3 (en) Modulation of huntingtin interacting protein 1 expression
WO2003062469A3 (en) Gene matn3 or matrilin-3 linked to osteoarthritis treatment
EG24959A (en) Indoles useful in the treatment of androgenreceptor related diseases.
AU2003223780A1 (en) Treatment for pompe disease
WO2004052309A3 (en) Modulation of stat 6 expression
AU2003266665A1 (en) Liquid crystal label, liquid crystal continuous body, and method of producing the liquid crystal label
AU2003222667A1 (en) 1,3-thiazoles as lxr modulators in the treatment of cardiovascular diseases
WO2004047741A3 (en) Modulation of iap-like expression
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
WO2004053083A3 (en) Modulation of fetoprotein transcription factor expression
WO2004048601A3 (en) Modulation of b7h expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP